The Therapeutic Goods Administration (TGA) has released a new online form for the clinical trial notification (CTN) scheme. When a clinical trial is investigating the use of a product within Australia, which is not on the Australian Register of Therapeutic Goods (ARTG), or on the ARTG yet being used outside its marketing approval conditions, these […]
了解更多
The George Institute was recently profiled in The Lancet; revered as one of the most prestigious, peer reviewed medical journals in the world. The Lancet Vol. 385 April 18, 2015 The feature ar […]
了解更多
ARCS is Australia’s primary professional development association for people working in the development of therapeutic goods. At the annual scientific congress held in Sydney recently, Dr Maria […]
了解更多
Sulfagenix, Inc., a United States based biotech, was able to tap into Australia’s world class research and development (R&D) facilities and expertise […]
了解更多
Over the last three years, The George Institute’s Associate Professor Zhang Puhong has led a very important and significant study on Type 2 diabetes in China, the ORBIT (Observational Registry for Basal Insulin Treatment) study. Professor Ji Linong, the chief physician of the department of endocrinology in Peking University People’s hospital, was the principal investigator. […]
了解更多
New legislation has taken into effect which simplifies the Hong Kong regulatory process for clinical trial application in that country
了解更多
Chronic obstructive pulmonary disorder (COPD) is now the third most frequent cause of death in the world; however the cause of this disease for a substantial proportion of patients remains unknown.
了解更多
Recently, 乔治临床( George Clinical )’s Project Operations team in Australia volunteered at an OzHarvest program […]
了解更多
